Regenerative medicine maker Organogenesis beats Q3 revenue estimates on rise in advanced wound care products

Organogenesis Holdings

06/11/2025 21:29

Overview

Organogenesis Q3 net product revenue rises 31%, beating analyst expectations

Adjusted net income for Q3 beats estimates, showing strong operational performance

Adjusted EBITDA for Q3 exceeds analyst expectations, reflecting robust performance

Outlook

Organogenesis updates 2025 net product revenue guidance to $500 mln-$525 mln

Company expects 2025 net income between $8.6 mln and $25.4 mln

Organogenesis anticipates 2025 adjusted EBITDA between $45.5 mln and $68.3 mln

Result Drivers

ADVANCED WOUND CARE GROWTH - Co reports 31% increase in revenue from Advanced Wound Care products, contributing significantly to overall revenue growth

STRATEGY EXECUTION - CEO attributes record revenue performance to strong execution and leveraging customer relationships

CMS PAYMENT RULE - Co believes it is well-positioned for 2026 due to CMS payment rule and ReNu product potential

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net product revenue
Beat
$150.50 mln
$134.10 mln (2 Analysts)
Q3 Adjusted Net Income
Beat
$23.20 mln
$8.20 mln (2 Analysts)
Q3 Net Income
$21.60 mln
Q3 Adjusted EBITDA
Beat
$30.10 mln
$17.40 mln (1 Analyst)
Q3 Operating Income
$20.70 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Organogenesis Holdings Inc is $8.00, about 50.4% above its November 5 closing price of $3.97

The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 55 three months ago

Press Release: ID:nGNX4CSC60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)